You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 162 No. 4, February 25, 2002 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (50)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Adverse Effects
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Evaluation of Prescribing Practices

Risk of Lactic Acidosis With Metformin Therapy

Amy T. Calabrese, PharmD; Kim C. Coley, PharmD; Stacey V. DaPos, MS; Dennis Swanson, MS; R. Harsha Rao, MD, FRCP(L)

Arch Intern Med. 2002;162:434-437.

Background  The risk of lactic acidosis during metformin therapy is linked to specific and well-documented conditions that constitute contraindications or precautions to use of the agent. We conducted a retrospective evaluation of metformin use to determine whether prescribing practices are in accord with published contraindications and precautions.

Methods  All patients admitted to the hospital during a 6-month period who received at least 1 dose of metformin were identified through hospital pharmacy records. Patient demographics and clinical characteristics were then evaluated to determine whether metformin was prescribed to patients possessing any of the risk factors associated with development of lactic acidosis.

Results  We identified 263 hospitalizations involving 204 patients who received at least 1 dose of metformin during inpatient admission. Patients had at least 1 absolute contraindication to metformin therapy in 71 admissions (27%). In 29 (41%) of these 71 admissions, treatment with metformin continued despite the contraindication. The most common contraindication, elevated serum creatinine concentration, was present or developed during 32 admissions (12%); however, metformin use was appropriately discontinued in only 8 (25%) of these 32 patients. Of the precautions against metformin use, concomitant administration of cationic agents was the most common, occurring in 97 admissions (37%).

Conclusions  Many patients are treated with metformin despite having clinical conditions that place them at risk for developing lactic acidosis. To minimize this risk, it is essential that prescribers develop a better understanding of the prescribing guidelines for metformin.


From the Department of Pharmacy and Therapeutics, University of Pittsburgh (Drs Calabrese and Coley and Mr Swanson); the Department of Pharmacy and Therapeutics, University of Pittsburgh Medical Center Health System (Dr Calabrese and Ms DaPos); and the Division of Endocrinology, Department of Medicine, University of Pittsburgh Medical Center (Dr Rao), Pittsburgh, Pa. Dr Rao is a member of the Speakers Bureau of Bristol Myers Squibb and has received honoraria for speaking at educational programs sponsored by the company.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 2002;162(4):487-488.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Randomized Trial of Electronic Clinical Reminders to Improve Medication Laboratory Monitoring
Matheny et al.
J. Am. Med. Inform. Assoc. 2008;15:424-429.
ABSTRACT | FULL TEXT  

Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?
Tahrani et al.
BMJ 2007;335:508-512.
FULL TEXT  

The Safety of Metformin in Heart Failure
Roberts and Ryan
The Annals of Pharmacotherapy 2007;41:642-646.
ABSTRACT | FULL TEXT  

Recent Metformin Ingestion Does Not Increase In-Hospital Morbidity or Mortality After Cardiac Surgery
Duncan et al.
Anesth. Analg. 2007;104:42-50.
ABSTRACT | FULL TEXT  

Changes in weight and glucose tolerance during treatment with mirtazapine.
Sharabash et al.
Diabetes Care 2006;29:170-170.
FULL TEXT  

Metformin's contraindications should be contraindicated
McCormack et al.
CMAJ 2005;173:502-504.
FULL TEXT  

Oral Agents for Type 2 Diabetes: An Update
Kimmel and Inzucchi
Clin. Diabetes 2005;23:64-76.
ABSTRACT | FULL TEXT  

Renal Status Among Patients Using Metformin in a Primary Care Setting
Kennedy et al.
Diabetes Care 2005;28:922-924.
FULL TEXT  

Review: metformin does not increase risk of lactic acidosis or increase lactate levels in type 2 diabetes
Kruse
Evid. Based Med. 2004;9:111-111.
FULL TEXT  

Management of Hyperglycemia in the Hospitalized Podiatric Medical Patient
Hein
J. Am. Podiatr. Med. Assoc. 2004;94:135-148.
ABSTRACT | FULL TEXT  

Management of Diabetes and Hyperglycemia in Hospitals
Clement et al.
Diabetes Care 2004;27:553-591.
FULL TEXT  

Does Metformin Interfere With Thiamine?
Alston
Arch Intern Med 2003;163:983-983.
FULL TEXT  

Insulin Sensitizers
Zangeneh et al.
Mayo Clin Proc. 2003;78:471-479.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2002 American Medical Association. All Rights Reserved.